MYEBOGA Conversations Ep 3 The Clare Wilkins Interview Pangea Biomedics 26 April 2020

Shea Prueger – Expectations & Inclusion

DIRECTOR, IBOGAINE ADMINISTRATOR – IBOGAINE REVELATIONS

Shea Prueger was introduced to ibogaine therapy by Eric Taub who she met while seeking treatment for suboxone addiction in 2010 while working as a full time fashion model. Following her own transformation, Shea began an apprenticeship under Lex Kogan at I Begin Again’s ibogaine facility in Guatemala and then Costa Rica, eventually taking over as director of the center.

Shea Prueger has ...

Continue Reading →

MYEBOGA Conversations Ep 2 The Dr Anwar Jeewa Interview All Things Ibogaine 13 April 2020

Shea Prueger – Expectations & Inclusion

DIRECTOR, IBOGAINE ADMINISTRATOR – IBOGAINE REVELATIONS

Shea Prueger was introduced to ibogaine therapy by Eric Taub who she met while seeking treatment for suboxone addiction in 2010 while working as a full time fashion model. Following her own transformation, Shea began an apprenticeship under Lex Kogan at I Begin Again’s ibogaine facility in Guatemala and then Costa Rica, eventually taking over as director of the center.

Shea Prueger has ...

Continue Reading →

MYEBOGA Conversations Ep 2 The Dr Anwar Jeewa Interview All Things Ibogaine 13 April 2020

Dr. Anwar Jeewa is the founder and director of Minds Alive Wellness Centre. He holds an Honours degree (2004) in Religion and Social Transformation from the University of Kwazulu-Natal (UKZN), for which he submitted a mini-dissertation entitled “Religion, Spiritual and Substance Abuse.” He also holds a Masters degree in Social Science (2006) from UKZN; the title of his dissertation was “The Treatment of Substance Abuse in Residential Centres in the 21st Century.” ...

Continue Reading →
Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

NEW YORK, April 16, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orally active, non-hallucinogenic molecule based on the psychedelic ibogaine.  

MindMed is developing 18-MC as a potential treatment for opioid ...

Continue Reading →

Universal Ibogaine Fighting Opioid Dependency with Plant-Based Medicine

Fighting Opioid Dependency with Plant-Based Medicine

This Universal Ibogaine profile is part of a paid investor education campaign.*

Overview

Universal Ibogaine is a Canadian company working to develop compounds to combat the opioid epidemic through plant-based medicine. The company aims to operate and franchise clinics around the world, offering ibogaine as a treatment for opioid-based withdrawals.

Opioids can be found in a number of licit and illicit ...

Continue Reading →
Page 52 of 110 «...2030405051525354...»
UA-77446339-1